Axumin PET/CT Scans Lead to Treatment Changes in Most Recurring Prostate Cancer Patients, Phase 3 Trial Shows

Axumin PET/CT Scans Lead to Treatment Changes in Most Recurring Prostate Cancer Patients, Phase 3 Trial Shows
In men suspected of recurring prostate cancer, imaging with Axumin (18F-fluciclovine) was able to accurately reveal sites of recurrence, which led to a change of treatment plans for 59 percent of the patients, topline results from the Phase 3 LOCATE trial show. Trial findings were recently presented in a poster, “Impact of positron emission tomography with 18F-fluciclovine on

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *